Research supports neurobiological rationale for evidence of neuroprotection obtained in completed Phase 2b clinical trials Protective effects on axonal degeneration and remyelination support potential role of teme ...
Statistically significant reductions in GGT and ALP in 400mg BID dose over 24-week treatment period (p<0.002 and p<0.001, respectively) GKT831 400mg BID significantly improved multiple quality of life metric ...
Study meets objective of demonstrating safety and pharmacodynamic response Confirmed excellent safety profile in combination with concomitant medications, with no serious adverse events Opens way for further de ...
Study meets objective of demonstrating safety and pharmacodynamic response Confirmed excellent safety profile in combination with concomitant medications, with no serious adverse events Opens way for further deve ...
Top Line Efficacy Results from Phase 2 Primary Biliary Cholangitis (PBC) Trial • 22% reduction in liver stiffness in PBC patients with liver fibrosis compared to a 4% increase for placebo (p=0.038), supports anti-fibr ...
Data Supports Temelimab's Potential to Treat Disease Progression in MS Long-term neuroprotective effects confirmed in patients treated up to two years Sustained benebits on cortical and thalamic atrophy and my ...
